CD276 and nonpapillary renal cell carcinoma: Finally, a nudemouse xenograft model was established and the nude mice were orally administeredsunitinib (40 mg/kg/d) to evaluate the in vivo effects of CD276 knockdownon the therapeutic efficacy of sunitinib against ccRCC.